Dr. Sham Mailankody

The list of available treatment options for multiple myeloma has grown in the past decade, However, as patients progress through therapy, it is important that oncologists not disregard the novel agents that are currently being investigated in clinical trials, according to Memorial Sloan Kettering Cancer Center’s Dr. Sham Mailankody.

’s sister publication, Mailankody explained how investigational drugs can play a role in the treatment of patients with myeloma as they advance past the initial lines of treatment.

I think with all these different treatment options, particularly in the relapsed/refractory setting, referring patients when appropriate to clinical trials of these novel treatments — for instance, the CAR-T cells and bispecific antibodies and others that are coming along that are not currently available as standard treatments but might provide significant clinical benefit for patients in the context of clinical trials &mdash; would be something else I think people should keep in mind as they see patients through their treatment course.

Articles

As patients progress through therapy, it is important that oncologists not disregard the novel agents that are currently being investigated in clinical trials, according to Memorial Sloan Kettering Cancer Center’s Dr. Sham Mailankody.

Dr. Sham Mailankody | Contributors

The Importance of Clinical Trials in Multiple Myeloma

Latest News